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Abstract: Background: Irritable bowel syndrome (IBS) is a functional disorder without any
pathological alteration, in which the alterations of the Candida/Saccharomyces ratio of the gut microbiota,
the balance of pro and anti-inflammatory cytokines and the brain-gut-microbiome axis are important
for the development and progression of IBS. The aim of the study was to identify natural products,
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including essential oils or hydrolates, which were contextually harmless for the gut beneficial
strains (e.g., Saccharomyces spp.) but inhibitory for the pathogenic ones (Candida spp.). Methods:
The effectiveness of 6 essential oils and 2 hydrolates was evaluated using microbiological tests, carried
out on 50 clinical isolates (Candida, Saccharomyces and Galattomyces species) and 9 probiotic strains
(Saccharomyces cerevisiae, Lactobacillus species, Akkermansia muciniphila and Faecalibacterium prausnitzii)
and immunological and antioxidant assays. Results: The study led to a mixture based on a 1/100 ratio
of Citrus aurantium var. amara essential oil / Vitis vinifera cv Italia hydrolate able to contextually reduce,
in a concentration-dependent manner, the ability of Candida species to form hyphal filaments and have
an interesting immunomodulatory and anti-oxidant action. This mixture can potentially be useful in
the IBS treatment promoting the restoration of the intestinal microbial and immunological balance.
Keywords: Candida species; Saccharomyces cerevisiae; Citrus aurantium var. amara essential oil;
Vitis vinifera cv Italia hydrolate; Akkermansia muciniphila
1. Introduction
Irritable bowel syndrome (IBS) is a gastrointestinal disorder that affects around 11% of the
population globally [1]. Despite being a chronic condition, contrary to the intestinal bowel disease (IBD)
that is a chronic inflammation of the intestine, IBS is a functional disorder without any pathological
alteration identified to date. However, IBS usually involves the brain-gut-microbiome axis but it can
develop after an enteric infection, with the stress exacerbating the disorder-associated symptoms [2].
Symptoms reported in either IBS or IBD patients are almost the same but differ with respect to their
extent. Generally, patients with IBD have more severe gastrointestinal symptoms compared with
IBS. [3]. There is a growing evidence that the gut microbiota alteration (e.g., decrease in the relative
abundance of a beneficial microorganism like Akkermansia muciniphila) and the psychology of the
patient are both important for the development and progression of IBS [2]. Since 1985, authors
have correlated the presence of Candida species in the intestinal tract with IBS [4] but only twenty
years later other authors showed that yeasts are able to cause IBS symptoms in patients sensitized
by Candida products, antigens and cross-antigens [5]. Other studies showed that the integration of
Saccharomyces cerevisiae in the diet of patients with IBS was able to significantly reduce abdominal
pain/discomfort and bloating and to improve the minimal clinically relevant threshold up to 10% [6–8].
In 2018, another study reported on the association between the relative abundance of A. muciniphila
and the pain modulation in IBS patients [9]. Finally, studies showed that the concomitant decrease in
the abundance of Saccharomyces species (i.e., S. cerevisiae and S. cerevisiae var. boulardii) and the increase
of Candida species in the intestinal or vaginal microbial communities correlated with a decreased
expression of the anti-inflammatory cytokine IL-10 and an increased expression of the pro-inflammatory
cytokines IL-6, IL-8 and TNF-α [10–13].
Integrated treatments for IBS include the combined administration of conventional and
complementary medications. The latter encompass Chinese medicine, homeopathy and
phytotherapy [14,15]. Several studies have recently evaluated the efficacy of natural products,
such as essential oils (EOs), in the treatment of IBS symptoms [16–22]. Some of the EOs studied
derive from aromatic plants of the Mediterranean area, such as Foeniculum vulgare, Pimpinella anisum,
Mentha × piperita and Citrus aurantium. The most active components of EOs are terpenes, whereas the
hydrophilic hydrolates (Hys) are by-products of EO distillation (also known as hydrolates or aromatic
waters) that contain up to 1% terpenic components of the EOs [23].
The aim of the present study was to evaluate the effectiveness of six EOs and two Hys, alone or in
combination, on both yeast (Candida, Saccharomyces and Galattomyces) isolates from IBS patients and
probiotic strains (Saccharomyces and Lactobacillus).
Nutrients 2020, 12, 1329 3 of 16
2. Materials and Methods
2.1. EO and Hy Natural Substances
The six EOs studied were as follows—Citrus lemon var. femminello (femminello lemon), supplied
by Exentiae Srl (Catania, Italy); C. aurantium var. amara (bitter orange), Citrus lemon (lemon)
and Citrus reticulata (mandarin), supplied by Misitano and Stracuzzi Company (Messina, Italy);
Monarda didyma (bee balm), supplied by the DISTAL of the Università di Bologna (Bologna, Italy) [24];
and Cinnamomum zeylanicum (cinnamon) supplied by APA-Ct (Forlì, Italy). All the Citrus species EOs
were obtained from their respective fruit epicarps by pressing, whereas the M. didyma EO was obtained
from the plant aerial parts and the C. zeylanicum EO was obtained from the cortex, both through
steam distillation. The two Hys studied were from M. didyma and Vitis vinifera cv Italia, supplied by
DISTAL of the Università di Bologna (Bologna, Italy). In particular, the M. didyma Hy was obtained
from the same distillation process as for the M. didyma EO [25], whereas V. vinifera, for the first time in
this study, was obtained according to the following protocol. Briefly, vegetal material (ripe berries
and grape-stalks) of the V. vinifera cv Italia was collected from the plants grown in the Sicily region,
monitored with a visual inspection to eliminate the parts apparently infested by bacteria and/or fungi
and cut in small pieces that were subjected to distillation in a Clevenger-type apparatus. After one
hour of distillation, only a sample of Hy (no EO was visualized) was collected.
2.2. Fungal and Bacterial Organisms
Fifty clinical isolates of fungal species (29 Candida albicans, 3 Candida glabrata, 1 Candida krusei,
4 Candida parapsilosis, 1 Candida zeylanoides, 8 Galactomyces species and 4 S. cerevisiae) were used,
which had been recovered from fecal samples of IBS patients at the Dipartimento di Gastroenterologia
e Epatologia, Ospedale G. da Saliceto of Piacenza, Italy. Patients were selected according to
ROME III diagnostic criteria for IBS; all patients presented abdominal pain/discomfort for almost
3 days/weeks. The 62% of IBS patients had diarrhea (> 3 discharges/day) and the 38% suffered
of constipation (<3 discharges/weeks). The Institutional Review Board of the Dipartimento di
Gastroenterologia e Epatologia, Ospedale “G. da Saliceto” of Piacenza, Italy, approved the protocol for
the obtainment of the patients’ fecal samples. Isolation and identification of fungal cultivable single-cell
pure colonies from stool sample of the IBS patients were performed as previously described [24].
Two fluconazole-resistant Candida tropicalis isolates were also used, obtained from clinical stool samples
of patients hospitalized at the Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome, Italy,
only to evaluate the effectiveness of natural products on the fungal morphology. For comparison
purposes, nine probiotic strains were included, five non-commercial strains (A. muciniphila DSMZ 22959,
Faecalibacterium prausnitzii DSMZ17677, Lactobacillus acidophilus LA3SACCO, Lactobacillus plantarum
ATCC 14917, Lactobacillus rhamnosus DSMZ 20021) and four commercial strains (S. boulardii CBS5926,
L. acidophilus LA-14, Lactobacillus casei RO215, Lactobacillus helveticus ROO52).
2.3. Broth Microdilution Susceptibility Testing
Broth microdilution (BMD) susceptibility tests was performed on all the 59 microbial organisms
according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) international
guidelines. RPMI broth (Irvine Scientific, St. Ana, CA, USA) was used for fungal organisms,
Man, Rogosa and Sharpe (MRS) broth (Sigma Aldrich, St. Louis, MO, USA) for Lactobacillus species
organisms and Brucella broth (Thermo Scientific, West Sussex, UK) for A. muciniphila and F. prausnitzii
organisms. All the bacterial probiotic strains were allowed to grow in an anaerobic condition. Briefly,
for each organism a cell suspension equal to 5 × 105 cfu/mL was obtained and 50 µL of the suspension
was dispensed in each well of a 96-well microtiter plate, which contained 50 µL of serial concentrations
ranging from 4% v/v (40 mL/L) to 0.06% v/v (0.6 mL/L) for each EO and from 50% v/v (500 mL/L)
to 1.67% v/v (16.7 mL/L) for each Hy. Tween 80 was utilized, at 0.05% v/v, as emulsifier for EO.
Suitable positive controls, only with culture medium, were made for each microbiological strain.
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After 24/48 h of incubation at 37 ◦C, minimum inhibitory concentration (MIC) values were determined
by spectrophotometric reading at 450 nm (EL808, Biotek, Winooski, VT, USA). To determine the
minimum cytocidal concentration (MCC) or the minimum fungicidal concentration (MFC), 5 µL of the
content of each well were seeded on standard medium agar plates, which were incubated at 37 ◦C for
24/48 h. For each natural substance (EO or Hy)/organism combination tested, the MIC was defined
as the lowest concentration that allowed a complete inhibition of the organism’s growth compared
with the growth in the substance-free control and the MCC as the lowest concentration that allowed
the death of 99.9% or more of the initial inoculum organism. All tests were performed in triplicate.
For C. aurantium var. amara, C. zeylanicum or M. dydima EOs, the BMD susceptibility tests were also
performed with co-cultures of two randomly selected organisms (i.e., C. albicans clinical isolate 3.1
and S. cerevisiae clinical isolate 14.3), starting from a 5 × 105 cfu/mL cell suspension obtained with a
mixture (ratio 1:1) of the two isolates. Then, 10 µL of the content of each well showing the organism(s)’
visible growth was seeded on the Brilliance Candida agar chromogenic medium (Oxoid, Thermo
Scientific, Basingstoke, UK) plates, which was incubated at 37 ◦C for 48 h. After incubation, the blue
(C. albicans) and purple (S. cerevisiae) colonies were counted to obtain the cfu/mL values for each
organism, respectively. Finally, to assess the effect of the C. aurantium var. amara EO and V. vinifera cv
Italia combination, a checkerboard broth microdilution susceptibility testing was performed with the
two cultured fungal organisms and sub-MIC concentration of C. aurantium var. amara EO (from 0.50%
v/v to 0.06%) and V. vinifera cv Italia Hy (from 0.25% v/v to 0.06% v/v). Then, the growth percentage at
each combination’s concentration was determined as the ratio between the number of cfu/mL obtained
for that concentration and the number of cfu/mL obtained for the substance-free control. Finally,
the content of each well was visualized directly with an inverted microscope and, after scraping of the
bottom (50 µL), with an optical microscope to study the fungal morphology.
2.4. Peripheral Blood Mononuclear Cell (PBMC) Collection and ELISA Testing
Peripheral blood mononuclear cells (PBMCs) from human blood derived from refrigerated,
banked healthy donor blood were collected with HISTOPAQUE-1077 (Sigma Aldrich, St. Louis,
MO, USA) solution according to the manufacturer’s protocol. After collection, 250 µL of a suspension
of 1.2 × 106 cells/mL were cultured in sextuplicate in a 48-well cell culture plate at 37 ◦C overnight.
PBMCs were incubated in the presence of serial dilutions of the V. vinifera Hy (from 50% v/v to
6.25% v/v) alone or in combination with C. aurantium var. amara EO (from 0.50% v/v to 0.06% v/v)
or with lipopolysaccharide (LPS, 1 µg/mL). Untreated PBMC cells were used as control. After 24 h
of incubation at 37 ◦C, the content of 4 replicates was mixed and centrifuged (400 × g for 10 min at
room temperature) to separate the cells from the culture medium, which was stored at −20 ◦C until
testing. The remaining two replicates were treated with 5 µL of Alamar Blue reagent (Invitrogen,
Carlsbad, CA, USA) in order to study the cellular vitality. To evaluate the expression of IL-6, IL-8,
TNF-α and IL-10 cytokines, ELISA tests (AVIVA Systems, San Diego, CA, USA) were performed using
100 µL of the aforementioned culture medium, according to the manufacturer’s instructions. In each
well, the content of cytokines was evaluated with optical reading using a microplate reading set to
450 nm. A calibration curve with six serial dilutions of the standard was included in each experiment,
which was repeated three times.
2.5. DPPH (2,2-Diphenyl-1-Picryl-Hydrazyl-Hydrate) Assay
The DPPH antioxidant assay was performed to evaluate the scavenging activity of the V. vinifera Hy.
Serial dilutions of the Hy (100 µL) were mixed with the 400-µM DPPH solution (100 µL) in a 96-well
microtiter plate. Methanol was used as a negative control. The mixtures were incubated for 30 min
at 37 ◦C in the dark and the change in spectrophotometric absorbance at 517 nm was measured.
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Mean values were obtained from triplicate experiments. The percentage of radical scavenging activity
per sample was calculated using the following equation:
% inhibition = [(A DPPH − A Extract)/ADPPH] × 100,
where A DPPH is the absorbance of the DPPH solution only and A Extract is the absorbance of the tested
sample. The IC50 value for the V. vinifera Hy was defined as the concentration of organic compound at
which 50% of DPPH radicals was quenched and was expressed as mean ± standard deviation.
2.6. GC-MS Analysis
A V. vinifera cv Italia Hy sample (50 mL) was extracted with diethyl ether (100 mL). The collected
organic layers dried over dry Na2SO4 and deprived of the solvent at reduced pressure furnished about
21.5 mg of an oily mixture (0.043%). The resulting Hy extract (1 mg) as well as a C. aurantium var. amara
EO sample (1 mg) were separately diluted in 1mL methanol and used for Gas Chromatography-Mass
Spectrometry (GC/MS) analysis. A GC-MS Perkin Elmer Clarus 500 instrument equipped with flame
ionization detector (FID) and a Restek Stabilwax fused-silica capillary column (length 60 m × 0.25 mm
ID) was employed. Helium was used as the carrier gas with a flow rate of 1 mL/min and the oven
temperature program was as follows—5 min at 60 ◦C then a gradient of 5 ◦C/minute to 220 ◦C. One µL
of sample was manually injected at 280 ◦C into the Gas Chromatography injector in the splitless mode.
Relative percentages for quantification of the components were calculated by electronic integration
of the GC-FID peak areas. Identification of the constituents was performed on MS library search
(Wiley and Nist). Linear retention indices (LRIs) of each compound were calculated using a mixture of
aliphatic hydrocarbons (C8-C30, Ultrasci) injected directly into GC injector.
2.7. Cytotoxicity Assays
Human gingival fibroblasts were obtained as described from by Radicioni G. et al. [26]. Cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum (FCS)
and were not used beyond the fifth step. The cytotoxicity of serial dilutions of the mixture of C. aurantium
var. amara EO (from 0.50% v/v to 0.03% v/v) and V. vinifera cv Italia Hy (from 50% v/v to 3.25% v/v)
for 24 and 48 h was evaluated. Untreated culture cells were used as control. Tetrazolium compound
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt; MTS] (Promega, Madison, WI, USA) was used, which was diluted in basic medium. Then, 1 × 104
cells were suspended in 200 mL of basic medium to be coated in 96-well cell culture plates and grown
at confluence for 24 h. Cell vitality was evaluated after the addition of the aforementioned serial
dilutions at 37 ◦C for 24 and 48 h. The MTS analysis was performed according to the manufacturer’s
protocols. Each experiment was done in triplicate.
2.8. Statistical Analysis
All data obtained in triplicate from each experiment were expressed as means± standard deviation
(SD). The response of S. cerevisiae and C. albicans to C. aurantium var amara EO concentration was fitted
by means of mathematical models, using the Sigma Plot 10 (Systat Software Inc., Chicago, IL, USA)
software. The best fitting model was chosen between linear and exponential decay function. The two
respective equations are:
y = y0 + ax (1)
y = a × exp(−bx) (2)
where: y0, intercept; a, slope (Equation (1)), initial level (Equation (2)); b, rate constant.
All the results obtained from the broth microdilution susceptibility testing were presented as
relative values, assuming the average of S. cerevisiae and C. albicans as positive control (Ctrl+) = 100%.
The data were treated with the GraphPad V 4.0 software. A two-way ANOVA for the factors clinical
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isolates (2 levels) and EO-Hy combined treatments (13 levels including Ctrl+) was run on these data.
The CoStat 6.3 package (CoHort Software, Berkeley, CA, USA) was used for the ANOVA.
All the results, obtained by cytotoxicity study, were expressed as mean percentage of vitality and
data treated with GraphPad V 4.0 software. The treated group means were compared by analysis of
variance (ANOVA) followed by a multiple comparison of means using the Dunnett’s test. Values with
p < 0.05 were considered significant.
3. Results
3.1. Antimicrobial Activities of EOs
Table 1 shows the MIC values of the 38 Candida species isolated from IBS patients against the EOs
of C. lemon, C. lemon var. femminello, C. reticulata, C. aurantium var. amara, C. zeylanicum and M. didyma
tested at the 0.50% v/v to 0.06% v/v concentrations.
Table 1. MIC values of selected clinical Candida spp. isolates against the essential oils in study.
Designation Isolates
MIC (% v/v)
CL1 CL-f2 CR3 CA-a4 CZ5 MD6
3.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
3.2 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.3 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.4 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.5 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.6 C. albicans >0.50 >0.50 >0.50 0.06 ≤0.06 0.25
3.7 Pikia kudriavzeii >0.50 >0.50 >0.50 0.25 ≤0.06 0.25
3.8 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.9 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.11 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.12 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.14 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.15 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
3.16 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.17 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.18 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.25
3.19 C. albicans >0.50 >0.50 >0.50 0.50 ≤0.06 0.50
5.2 C. parapsilosis >0.50 >0.50 >0.50 0.50 ≤0.06 0.12
5.3 C. zeylanoides >0.50 >0.50 >0.50 0.50 ≤0.06 0.12
5.4 C. parapsilosis >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
5.5 C. parapsilosis >0.50 >0.50 >0.50 >0.5 ≤0.06 0.25
5.6 C. parapsilosis >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
8.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
9.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
10.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50
10.2 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50
10.3 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
10.4 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
10.5 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
10.6 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
10.7 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
10.8 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
11.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
11.2 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
14.1 C. albicans >0.50 >0.50 >0.50 >0.50 ≤0.06 0.25
18.2 C. glabrata >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50
18.5 C. glabrata >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50
18.6 C. glabrata >0.50 >0.50 >0.50 >0.50 ≤0.06 0.50
MIC values were found to be equal to the MFC values for all the isolates tested. 1C. limon. 2C. limon var. femminello.
3C. reticulata. 4C. aurantium var. amara. 5C. zeylanicum. 6M. dydima.
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The MIC50 values were > 0.50% v/v for C. lemon, C. lemon var. femminello and C. reticulata, 0.50% v/v
for C. aurantium var. amara, ≤ 0.06% v/v for C. zeylanicum and 0.25% v/v for M. didyma.
Table 2 shows the MIC values of the 7 probiotic strains and the 12 Galactomyces species and
S. cerevisiae isolates against the EOs of C. aurantium var. amara, C. zeylanicum and M. didyma (the only
three EOs showing better activity) tested at the 4.0% v/v to 0.06% v/v concentrations. It was chosen to
test lower EO concentrations for the isolates from pathogenic species (i.e., Candida species) and higher
EO concentrations for the isolates from beneficial species (i.e., probiotic or Galactomyces/S. cerevisiae
species). This choice would ensure the activity toward the pathogenic species and non-toxicity toward
the beneficial species eventually present in the gut microbiota of IBS patients. The MIC50 values were
> 4.0% v/v for C. aurantium var. amara, 0.50% v/v for M. didyma and ≤ 0.06% v/v for C. zeylanicum.
Table 2. MIC values of commercial probiotic strains and clinical beneficial bacterial strains against the
essential oils of M. dydima, C. aurantium var. amara, C. zeylanicum.
Strain Probiotic Commercial Strains
MIC (% v/v)
CA-a 1 CZ 2 MD 3
CBS5926 S. boulardii >4.00 ≤0.06 0.50
LA3SACCO L. acidophilus >4.00 ≤0.06 2.00
LA-14 L. acidophilus >4.00 ≤0.06 0.50
ATCC14917 L. plantarum >4.00 ≤0.06 1.00
DSMZ 20021 L. rhamnosus >4.00 ≤0.06 0.50
R0215 L. casei >4.00 ≤0.06 1.00
R0052 L. helveticus 0.12 ≤0.06 0.12
Designation Beneficial Clinical Strains
13.0 Galactomyces species 2.00 ≤0.06 0.25
17.1 Galactomyces species >4.00 ≤0.06 2.00
17.5 Galactomyces species 4.00 ≤0.06 0.50
17.7 Galactomyces species >4.00 ≤0.06 0.50
17.8 Galactomyces species >4.00 ≤0.06 0,50
17.9 Galactomyces species >4.00 ≤0.06 0.50
17.10 Galactomyces species 4.00 ≤0.06 0.50
17.11 Galactomyces species 4.00 ≤0.06 1.00
14.3 S. cerevisiae 1.00 ≤0.06 0.25
14.5 S. cerevisiae 1.00 ≤0.06 0.25
14.9 S. cerevisiae 1.00 ≤0.06 0.50
14.11 S. cerevisiae 2.00 ≤0.06 0.25
MIC values were found to be equal to the MFC values for all the isolates tested. 1 C. aurantium var. amara,
2 C. zeylanicum, 3 M. dydima.
Based on these findings, the C. aurantium var. amara, C. zeylanicum and M. didyma EOs were tested
against two co-cultured clinical isolates of C. albicans (clinical isolate 3.1) and S. cerevisiae (clinical
isolate 14.3), which were representative of both pathogenic and beneficial isolates included in the study.
Using 4% v/v to 0.015% v/v concentrations, it was found that MIC and MFC values were equal for all the
three EOs. Expectedly, the C. zeylanicum EO was the most effective (MFCs for C. albicans and S. cerevisiae,
0.015% v/v and 0.06% v/v, respectively), compared to the M. didyma EO (MFCs for C. albicans and
S. cerevisiae, 1% v/v) and the C. aurantium var. amara EO (MFCs for C. albicans and S. cerevisiae, 2% v/v).
Therefore, the inhibitory capability of the C. aurantium var. amara EO was further investigated by
counting the cfu/mL of both C. albicans and S. cerevisiae recovered after their incubation with sub-MIC
concentrations (≤ 2% v/v) of the EO. Figure 1 shows that the 2% concentration of C. aurantium var.
amara EO was able to completely suppress both organisms. Interestingly, S. cerevisiae exhibited an
exponential trend of increased tolerance to the EO (R2 = 0.71) that was statistically significant and
different (p < 0.05) from the linear trend of C. albicans (R2 = 0.65).
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Figure 1. cfu/ml of Saccharomyces cerevisiae (filled symbol) and Candida albicans (empty symbol) in
response to Citrus aurantium var. amara essential oil (EO) concentration. Solid line, exponential decay
function (Equation (2)) describing S. cerevisiae abatement at increasing EO concentration. Dashed line,
linear function (Equation (1)) describing C. albicans abatement at increasing EO concentration. (+) and *,
significant at p ≤ 0.10 and p ≤ 0.05, respectively.
As expected, neither M. dydima nor V. vinifera cv Italia Hys showed antimicrobial activities against
all the 59 microbial strains above mentioned.
3.2. Immunomodulatory and Antioxidant Activities of the V. vinifera cv Italia Hy
The immunomodulatory activities of both V. vinifera cv Italia and M. didyma Hys were studied,
using human PBMCs. Data showed that PBMCs treated with M. didyma Hy died whereas those treated
with V. vinifera cv Italia Hy did not lose viability. Therefore, the effects of the V. vinifera cv Italia Hy
and, in parallel, LPS alone or in combination with the Hy has been investigated, on the levels of IL-10
and TNF-α produced by PBMCs.
Table 3 summarizes both the mean and standard deviation values of IL-10 and TNF-α under the
tested conditions, while Figure 2 shows the relationship of the two cytokines in each condition.
Table 3. IL-10 and TNF-α values of both peripheral blood mononuclear cells (PBMCs) and PBMCs
stimulated with lipopolysaccharide (LPS) when treated with the Hy of V. vinifera alone or in combination
with the EO of C. aurantium ar. amara.
Simple VV-Hy
1 CA-EO2 Mean (± St. Dev.)3
(%v/v) (%v/v) IL-10 TNF-α
PBMCs - - 2.60 (± 0.07) 47.98 (± 2.80)
50.00 - 16.40 (± 0.8 ) 199.50 (± 12.30)
25.00 - 53.80 (± 1 2 ) 375.80 (± 7.20)
12.50 - 14.51 (± 0.60) 1126.80 (± 14.80)
6.25 - 3.28 (± 0.30) 620.60 (± 33.20)
PBMCs + LPS - - 518.00 (± 3.0 ) 2002.90 (±14.40)
50.00 - 5.93 (± 0.30) 238.70 (± 7.50)
25.00 - 90.90 (± 3.60) 1846.30 (± 20.30)
12.50 - 83.70 (± 4.20) 2221.50 (± 2.60)
6.25 - 46.30 (± 0.90) 2148.20 (± 195.6)
50.00 0.5 0.64 (± 0.14) 0.64 (± 0.14)
25.00 0.25 119.00 (± 0.46) 977.91 (± 16.60)
12.50 0.12 269.53 (± 4.07) 1901.90 (± 0.00)
6.25 0.06 403.23 (± 37.65) 2143.01 (± 25.09)
1 hydrolate of V. vinifera cv Italia, 2Essential oil of C. aurantium var. amara, 3values are expressed as pg/mL.
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Figure 2. Variation of the amount of cytokines IL-10 and TNF-α in the medium culture of PBMCs
treated with scalar dilutions of the V. vinifera cv Italia Hy alone or in combination w th EO and/or LPS.
The circle-shaped indicators refer to the samples treated with the Hy only; the squares are referred
to th samples tre ted with th Hy plus LPS, while the triangles show th samples tre ted with Hy
plus the EO of C. aurantium va . amara plus LPS. The white r ombus is the untreated control and the
bl ck rhombus is the control tr ated with LPS. Letters a, b, c and d indi ate samples treated with scalar
dilution of the Hy (50% v/v, 25% v/v, 12.50% v/v and 0.06% /v respectively). Letters , f, g and h are
referred to samples treated with scalar dilution of the Hy (50% v/v, 25% v/v, 12.50 v/v and 0.06% v/v
respecti ely) and LPS (1 µgr/mL). Letters i, l, m and n are referred to PBMCs treated with a 1:100 v/v
mixture of the Hy, (50% v/v, 25% v/v, 12.50 v/v and 0.06% v/v respectively) and the EO (0.50% v/v,
0.25% v/v, 0.12% v/v and 0.06% v/v respectively) plus LPS.
As shown in Table 3, the levels of IL-10 and TNF-α in untreated PBMCs were 2.6 ± 0.07 pg/mL and
47.98 ± 2.8 pg/mL, respectively, whereas those in PBMCs treated with LPS were 518 pg/mL ± 3.0 pg/mL
and 2002.9 pg/mL ±14.4 pg/mL. The IL-10 and TNF-α values of PBMCs treated with 50% of the
V. vinifera cv Italia Hy and those of PBMCs treated with both 50% of the V. vinifera cv Italia Hy and LPS
had values close to those of the untreated PBMCs (Figure 2, letters a and e in CTR circle). The values of
PBMCs treated with concentrations other than 50% of V. vinifera cv Italia Hy alone varied based on the
Hy concentration tested. In particular, only TNF-α values were higher than those of PBMCs, while both
IL-10 and TNF-α values were lower than those of PBMCs stimulated with LPS alone (Figure 2, letters
b, c, d in Hy circle). PBMCs treated with concentrations other than 50% of V. vinifera cv Italia Hy in
combination with LPS had a strong reduction of IL-10 values, compared to PBMCs stimulated with
LPS only.
The DPPH assay was used to study the anti-oxidant activity of the V. vinifera cv Italia Hy. Data show
that the Hy exhibited low activity because of an IC50 of 4 ×10-3 ± 0.001 µg/µL of organic component,
which corresponds to the one present in a 95.6 ± 2.1% v/v of Hy solution (i.e., to the one of the almost
pure Hy).
3.3. Effectiveness of the C. aurantium var. Amara EO and V. vinifera cv Italia Hy Combination
Figure 3 shows the results of checkerboard BMD testing of C. aurantium var. amara EO (from 0.50%
v/v to 0.06% v/v) and V. vinifera cv Italia Hy (from 25% v/v to 6.25% v/v) against C. albicans (clinical
isolate 3.1) and S. cerevisiae (clinical isolate 14.3). As showed by ANOVA test, concentrations equal
to or lower than 0.12% v/v for EO, regardless of Hy concentration, did not produce any statistically
significant inhibition for the two isolates, whereas for concentrations of the EO higher than 0.12% v/v
the isolate of S. cerevisiae shows a statistically significant growth inhibition.
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H++ 
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8.5 C. glabrata Y Y Y Y Y Y 
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C. 
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hyphae and pseudo-hyphae, H++ = a lot of hyphae and pseudo-hyphae. 
Figure 3. Relative growth of the clinical isolates of C. albicans (3.1) and S. cerevisiae (14.3) when cultured
in presence of scalar dilutions of both the EO of C. aurantium var amara and the Hy of V. vinifera cv Italia.
The values are relative to the positive control (CTR+) and are expressed in percentage. The average of
the two isolates’ positive controls is set at 100%.
Then, 1:100 v/v mixtures of EO (0.50% v/v to 0.06% v/v) and Hy (50% v/v to 6.25%) were evaluated
for morphological microscopy examination and five of seven Candida species (exceptions were one
C. glabrata and one C. tropicalis [0.4 R]) isolates displayed a concentration-dependent reduced capability
of forming hyphal filaments (Table 4). As expected, any morphological alterations for the S. cerevisiae
isolate tested were observed. Additionally, none of the EO/Hy mixture concentrations was able to
affect the nine probiotic isolates as well the A. muciniphila and F. prausnitzii isolates (potentially usable
as probiotics).
Table 4. Effectiveness of a mixture of C. aurantium var. amara EO and V. vinifera cv italia Hy on the
morphology of clinical fungal species.
Designation Fungal Species C. aurantium va. amara (% v/v) EO + V. vinifera Hy
0.50 + 50 0.25 + 25 0.12 + 12.5 0.06 + 6.25 0.03 + 3.17 CTR
0.3R 1 C. tropicalis Y H H H H H++
0.4R 1 C. tropicalis
H++
(no adhesion)
H++
(no adhesion)
H++
(no adhesio )
H++
(no adhesion)
H++
(no adhesion) H++
3.1 C. albicans Y H H+ H+ H+ +
10.1 C. albicans Y H H+ H+ H++ H++
3.15 C. albicans Y Y Y Y H+ H++
8.5 C. glabrata Y Y Y Y Y Y
3.7 C. krusei Y Y Y Y Y Y
5.1 C. parapsilosis Y Y Y Y Y Y
1 fluconazole resistant strain, Y =Presence of a lot of yeast; H = Presence of rare hyphae; H+ = few hyphae and
pseudo-hyphae, H++ = a lot of hyphae and pseudo-hyphae.
It was assessed whether the EO/Hy mixture concentrations had immunomodulatory activities on
human PBMCs when used in combination with LPS.
As shown in Figure 2, linear decrease of IL-10 and TNF-α values were observed in PBMCs
treated with both LPS and different concentrations of the EO/Hy mixture. In particular, at the lowest
concentration tested (6.25% v/v Hy and 0.625% v/v EO) the values of cytokines are similar to those
expressed by the PBMC stimulated with LPS only. Whereas, by increasing the tested concentrations
of the EO/Hy mixt r , the IL-10 and TNF-α values decrease linearly (Figure 2, letters l, m and n in
Mix + LPS circle) until they become similar to those of the PBMCs (Figure 2, letter i in CTR circle).
Furthermore, it was investigated whether the EO/Hy mixture concentrations had cytotoxic
activities on human gingival fibroblasts. As shown in Figure 4, none of the concentrations tested was
capable of producing statistically significant effects on the fibroblasts after 24 h and 48 h of incubation.
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1 Elution order on polar column; 2 Linear Retention indices measured on polar column; 3 Linear 
Retention indices from literature; 4 Essential oil of C. aurantium var. amara, 5 hydrolate of V. vinifera cv 
Italia, * Normal Alkane RI. The %VV-Hy are referred to the fraction of organic components extracted 
from 50mL of Hy.  
4. Discussion 
Few studies have been done on the effectiveness of essential oils in treating patients with IBS 
and most of them have been made in the last 10 years. In addition to the now known properties of 
the essential oil of Mentha × piperita that make it an interesting treatment not only for IBD but also for 
IBS [22], other essential oils, especially those obtained from aromatic plants with known carminative 
activity, have been recently studied in the treatment of IBS. Mahboubi M. [18] reviewed the action of 
Figure 4. Cytotoxicity tests. Cytotoxicity assays performed with a Cell Titer Blue viability assay on
human gingival fibroblasts at 24 (A) and 48 h (B) upon cell synchronization (24 h). Cells were treated
with scalar dilution of a 1:100 v/v mixtures of Citrus aurantium var. amara EO (0.50% v/v to 0.06% v/v)
and Vitis vinifera cv Italia Hy (50% v/v to 6.25%).
Finally, GC-MS analyses performed on both the EO and the organic fraction from Hy showed that
the major component of EO was the limonene (93.93%) and the major components of the Hy were
limonene (17.68%), cis-geraniol (25.40%) and β-linalool (38.81%) (Table 5).
Table 5. Chemical composition (%) of C. aurantium var. amara EO and V. vinifera Hy.
Name 1 LRI 2 LRIlit 3 %CA-EO 4 %VV-Hy 5
α-pine 1038 0.57 0.39
β-pine 1134 0.73 -
sabine e 1152 0.36 -
β-myrcene 117 2.37 -
limone e 123 93. 17.68
γ-terpinene 1270 0.26 -
o-cymene 1295 0.15 -
cis-linaloloxide 1433 1420 - 0.85
decanal 1520 1515 0.22 -
β-linalol 1553 1547 0.21 38.81
linalyl acetate 1572 1575 0.77 -
α-terpineol 1705 1700 0.22 7.55
borneol 1724 1717 - 0.69
cis-geraniol 1831 1823 - 25.40
humulene-1,2-epoxide 2018 NA* - 2.55
d-nerolidol 2030 2023 0.21 -
thymol 2198 2189 - 1.75
carvacrol 2231 2225 - 4.33
SUM 100.00 100.00
1 Elution order on polar column; 2 Linear Retention indices measured on polar column; 3 Linear Retention indices
from literature; 4 Essential oil of C. aurantium var. amara, 5 hydrolate of V. vinifera cv Italia, * Normal Alkane RI.
The %VV-Hy are referred to the fraction of organic components extracted from 50 mL of Hy.
4. Discussion
Few studies have been done on the effectiveness of essential oils in treating patients with IBS
and most of them have been made in the last 10 years. In addition to the now known properties
of the essential oil of Mentha × piperita that make it an interesting treatment not only for IBD but
also for IBS [22], other essential oils, especially those obtained from aromatic plants with known
carminative activity, have been recently studied in the treatment of IBS. Mahboubi M. [18] reviewed
the action of Zataria multiflora EOs in the treatment of gastrointestinal problems, especially in IBS.
As reported, 60 drops oral daily dose of Z. multiflora essential oil (2%) can relieve the symptoms of IBS
without any adverse effects. Portincasa P. et al. [20] and Di Ciaula A. et al. [16] investigated the activity
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of the EOs of F. vulgaris in association with Curcuma longa extract in IBS patients. The two studies
concluded that the administration of these natural compounds significantly improved symptoms and
quality of life in IBS patients within 2 months from the treatment. Mosaffa-Jahromi M. et al. [19] have
demonstrated that a treatment of 4 weeks with encapsulated P.anisum EO (200 mg for 3 times a day) is
able to improve IBS symptoms better than placebo or M. piperita capsules (Colpermin®) (p < 0.0001).
Finally, Agah S. et al. [27] studied the effect of 20 drops of Cuminum cyminum EO on 57 patients with
IBS selected according to the ROME II diagnostic criteria. Data showed that IBS symptoms had a
statistically significant reduction during and after treatment.
According to the most recent literature, at the base of the IBS there is an alteration of the intestinal
microbiota in favor of microbial strains generally present in lower percentages (especially fungal
strains). For this reason, we chose to investigate the antimicrobial action of some EOs and Hys
on both fungal and probiotic strains. All the natural products studied were obtained from plants
potentially cultivable in the Mediterranean area with the exception of C. zeylanicum, which was taken
as a reference given its known high antimicrobial activity [28]. Furthermore, considering that the
IBS symptoms are deeply conditioned by an altered brain-gut-microbiome axis, some of the EOs
in study have been chosen to potentially act not only on microbial strains but also on the central
nervous system (CNS). Therefore, 4 out of the 6 EOs studied belong to the Citrus genus which, besides
being a genus widely present in Italy, is mainly used in aromatherapy in the treatment of nervous
disorders and anxiety. Particularly, the C. aurantium var. amara EO is used as a natural mild sedative,
hypnotic and anticonvulsant agent. It is used in treating insomnia, sleep disorders, anxiety, epilepsy
and seizures. It has been also reported for its anti-spasmodic effects and, thanks to the presence of
limonene, for its gastro-protective and ulcer healing actions by increasing the gastric production of
mucus, which is useful as a secondary intervention in the treatment of chronic inflammatory diseases.
Similarly, C. limon and C. reticulata EOs are used in phytotherapy to relieve symptoms of anxiety [29].
Instead, the M. didyma is an aromatic plant included in the BELFRIT (Belgium, France and Italy) list,
native of Northern Europe but cultivable in Italy; its EO has two phenols as major components (thymol
and carvacrol) and therefore shows a marked antimicrobial activity [24].
The study of MICs (and MCCs), against clinical isolates of Candida spp., indicates that no EOs
belonging to the Citrus genus have an action comparable to that of M. didyma (MIC50 = 0.25% v/v) and
C. zeylanicum (MIC50 ≤ 0.06 % v/v) EOs. All the EOs obtained from Citrus have a MIC50 > 0.5 % v/v
with the exception of the EO of C. aurantium var. amara that showed a MIC50 = 0.50% v/v, slightly
different from that of M. didyma. Based on this result, the action of the 3 EOs with major antifungal
activity has been tested towards both probiotic strains and beneficial clinical isolates belonging to the
intestinal microbiota (Table 2). The data indicate that both the above are generally more resistant to the
action of EOs than the pathogenic fungal isolates. In particular, the EO of C. aurantium var. amara has a
MIC50 value (MIC50 ≥ 4% v/v) at least 3 dilutions higher against the beneficial clinical isolates than
against the clinical isolates of Candida species (MIC50 = 0.50% v/v).
These data are in agreement with those available in the literature highlighting that the probiotic
strains have higher MIC values than the pathogenic strains [3,30,31] and that thanks to the different
MIC values between probiotic and pathogenic strains it is possible to administer probiotics and EOs
together to cure pathogenic infections in human gut [32].
To evaluate the effectiveness of the three best EOs on the rebalance of beneficial and pathological
clinical strains, we performed the BMD susceptibility tests using the EOs of C. aurantium var. amara,
M. dydima and C. zeylanicum against two co-cultured randomly selected fungal clinical isolates
(C. albicans clinical isolate 3.1 and S. cerevisiae clinical isolate 14.3).
The choice to co-culture one clinical isolate of C. albicans with one of S. cerevisiae is motivated
by the evidence that in IBS patients a greater colonization of fungal strains belonging to the genus
Candida, at the expense of the ones of S. cerevisiae, has been demonstrated [4,5,33]. If on the one hand it
is known that S. cerevisiae is a yeast generally well represented in the intestinal microbiota of healthy
subjects that, besides having a known anti-inflammatory action, is able to compete for the territory
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with Candida spp., on the other we know that IBS patients are characterized by a higher abundance
of C. albicans (61.8%) compared to healthy subjects (48.75%) [33]. Moreover, IBS C. albicans isolates
were different from those of healthy subjects not only genotypically but also phenotypically as these
clinical isolates of C. albicans were able to grow at high temperatures and low pH compared to those
isolated from healthy subjects [33]. These data suggest that IBS could be characterized by the presence
of potentially virulent C. albicans strains and motivate our choice.
Our data show that, when co-cultured, the two fungi have the same MFC but, by analyzing the
fungal growth in the presence of sub-MIC of C. aurantium var. amara EO, it is possible to identify a
different modulating action of this EO towards the two clinical strains. In particular, for concentrations
equal to or lower than 2% v/v of C. aurantium var. amara EO, the strain of C. albicans is significantly
more inhibited than that of S. cerevisiae (Figure 1). Therefore, this activity could be useful in an attempt
to rebalance the relative abundance of each clinical species in IBS patients.
The variation of the intestinal microbiota also involves the variation of the intestinal inflammatory
microenvironment. Indeed, it is known that the decrease in S. cerevisiae and the increase in Candida
species is generally related to an increase in the pro-inflammatory pattern in IBS patients [5].
As described in Results, an interesting immunomodulatory and anti-oxidant property of the V. vinifera cv
Italia Hy was identified; on the contrary, the Hy of M. dydima was excluded because toxic for human
PBMCs culture.
The V. vinifera is a plant genus recognized by both traditional and consolidated use for the treatment
of microcirculation problems thanks to its important anti-oxidant, anti-inflammatory, spasmolytic
and immunomodulated actions. The first sources on the use of V. vinifera as medicament are the
Egyptian papyri, the Sumerian tablets, the writings of Hippocrates of Cos, Celsus, Galen and Paracelsus.
Currently, natural products obtained from V. vinifera are found on the market in the form of dry
extracts or soft aqueous extracts [34–36] but it is hard to find the hydrolate of V. vinifera because it
is an unusual natural product obtained from the distillation of a non-aromatic plant. This means
that our data are innovative showing that it is obtained from a still unexplored natural product that,
thanks to its immunomodulatory and anti-oxidant activity, could be exploited in the chronic low-grade
inflammation that establishes in patients with IBS [37].
Tests developed to identify the best combination of C. aurantium var. amara EO and V. vinifera cv
Italia Hy have shown that a serial dilution of a mixture made with a 1:100 ratio of the two natural
products (starting from a concentration of 0.50% v/v of C. aurantium var. amara EO and 50% v/v of
V. vinifera cv Italia Hy) caused an interesting inhibition of the ability of C. albicans species to form
hyphae (Table 4). As reported in a recent review, the morphological plasticity of Candida albicans
cells makes this fungus able to adapt to the different niches present in the gut of the host organisms.
Generally, the production of C. albicans hyphae and pseudo-hyphae is typical of cellular models of
virulence specialized in the commensalism [38]. The above are in agreement with what has been
observed on C. albicans clinical isolates of IBS patients [33] where the gut microbiota is characterized by
a greater abundance of C. albicans cells, more virulent than in healthy subjects. In this context, the use
of one of the effective serial dilutions based on C. aurantium var. amara EO and V. vinifera cv Italia Hy,
able to inhibit the production of hyphae and pseudo-hyphae of C. albicans strains, could prove to be
successful in IBS treatment; especially considering that the same serial dilution of the two natural
compounds also has the ability to linearly inhibit in a concentration-dependent manner the production
of the IL-10 and TNF-α cytokines from PBMCs grown in presence of the pro-inflammatory stimulus
(LPS) (Figure 2). Rather than the use of intestinal cells such as CaCo2, the ex vivo experiments carried
out on PBMC were performed in order to evaluate the action of natural compounds in modulating the
human systemic immunological response. This latter activity would enhance the effectiveness of the
mixture inducing the reduction of the pro-inflammatory framework generally present in patients and
able to favoring the growth of Candida species and promoting the establishment of the appropriate
microenvironment for the development of beneficial probiotic strains including A. muciniphila and
F. prausnitzii recently proposed as markers of the syndrome [39].
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Finally, the mixture identified in this study appears to be suitable for an oral use in patients with
IBS because, in addition to showing no in vitro cytotoxic activity (Figure 4), it appeared to be composed
mainly of the monoterpene limonene because all the other chemical constituents were present in traces
(Table 5). In a study, the limonene has been designated as a compound with low oral toxicity based on
its lethal dose (LD50) and repeated-dose toxicity studies. Therefore, except for topical applications,
for which attention must be paid to avoid its irritating potential, the use of limonene is widely granted
in the pharmaceutical, cosmetic and food industries for its many properties [40].
5. Conclusions
In conclusion, even though further in vivo studies to evaluate the effectiveness as well as the
possible presence of adverse and/or toxic effects are necessary, our study concludes that a mixture
based on C. aurantium var. amara EO and V. vinifera cv Italia Hy (ratio 1:100) can be useful in the
treatment of IBS. The use of this mixture in an integrated treatment with conventional treatments could
favor the growth of both probiotic and beneficial gut strains, disfavoring pathogenic fungal strains and
rebalancing the intestinal inflammatory microenvironment through the reduction of the expression of
IL-10 and TNF-α cytokines and, in parallel, of the pro-inflammatory microenvironment.
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